Stock PRQR PROQR THERAPEUTICS N.V.
Add to a list
To use this feature you must be a member
Log inSign up

News ProQR Therapeutics N.V.

Equities

PRQR

NL0010872495

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-10 pm EDT 		5-day change 1st Jan Change
1.98 USD -1.00% Intraday chart for ProQR Therapeutics N.V. -1.49% 0.00%
May. 09 Transcript : ProQR Therapeutics N.V. - Special Call
May. 09 ProQR Therapeutics N.V. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Transcript : ProQR Therapeutics N.V. - Special Call
ProQR Announces First Quarter 2024 Operating and Financial Results
GL
ProQR Therapeutics N.V. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
ProQR Announces Preclinical Proof of Concept Data for AX-0810 Axiomer™ RNA Editing Program Targeting NTCP for Cholestatic Diseases
GL
ProQR Announces Preclinical Proof of Concept Data for AX-0810 Axiomer? RNA Editing Program Targeting NTCP for Cholestatic Diseases
CI
ProQR Highlights Upcoming Presentations on Axiomer RNA Editing at ASGCT 27th Annual Meeting
AQ
ProQR Therapeutics N : AGM 2024 Notice and Agenda
PU
ProQR Therapeutics N : AGM 2024 AoA one-tier Board English redline
PU
ProQR Therapeutics N : AGM 2024 AoA one-tier Board English clean
PU
ProQR Therapeutics N : AGM 2024 Board Compensation Policy one-tier Board
PU
ProQR Therapeutics N : AGM 2024 Equity Incentive Plan one-tier Board redline
PU
ProQR Therapeutics N : AGM 2024 Equity Incentive Plan one-tier Board clean
PU
ProQR Nominates Martin Maier, PhD to Board and Announces Annual Meeting of Shareholders to be Held May 22, 2024
GL
ProQR Therapeutics N.V. Announces Stepping Down of Dinko Valerio as Chairperson
CI
ProQR Highlights Upcoming Presentations on Axiomer™ RNA Editing at ASGCT 27th Annual Meeting
GL
ProQR Therapeutics N : AGM 2024 Explanatory Notes
PU
ProQR Therapeutics N : AGM 2024 POA Registered Shareholders
PU
ProQR Achieves Successful Defense of New Challenge to its Axiomer IP Portfolio
AQ
ProQR Achieves Successful Defense of New Challenge to its Axiomer™ IP Portfolio
GL
Chardan Raises ProQR Therapeutics' PT to $2.50 From $2, Says ADAR-Based Therapeutics to Enter Clinical Development, Keeps Buy Rating
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. PRQR Stock
  4. News ProQR Therapeutics N.V.
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW